Best pharmaceutical companies in Seattle, WA

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co.,

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women's Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world. Pharmaceutical The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL CONSTA (risperidone), a long-acting injectable, and INVEGA (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN (levofloxacin) and FLOXIN (ofloxacin), both in the anti-infective field; CONCERTA (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a novel delivery system. Medical Devices and Diagnostics The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis' circulatory disease management products; DePuy's orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon's surgical care and women's health products; Ethicon Endo-Surgery's minimally invasive surgical products; LifeScan's blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics' professional diagnostic products and Vistakon's disposable contact lenses.

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. The company is driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. Merck delivers vaccines, medications, and consumer and animal health products that can help millions around the world. Merck was founded in 1891 and is headquartered in Kenilworth, NJ.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Cytel is a multinational statistical software developer and contract research organization, headquartered in Cambridge, Massachusetts, USA.

Husa Liquidating Corporation, formerly HearUSA, Inc., provides a range of hearing aids, with emphasis on digital technology along with assessment and evaluation of hearing. The Company operates in three segments: the Company-owned centers, the network ...

Covance Inc. is a global contract research organization recognized for being the world's most comprehensive drug development company. It has a team of professionals that are dedicated to advancing healthcare and delivering fast and innovative medical solutions to patients and healthcare providers. The company also offers laboratory testing services to the chemical, agrochemical, and food industries. It is also a market leader in central laboratory, toxicology, and discovery services.

Tilray is a global leader in medical cannabis research and production dedicated to providing safe, consistent and reliable therapy to patients. We are the only GMP certified medical cannabis producer currently supplying products to thousands of patient...

Gilead Palo Alto, Inc. develops and commercializes small molecule drugs for the treatment of cardiovascular diseases. It develops advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. The company offers Ranexa (ranolazine extended-release tablets), which is used for the treatment of chronic angina; and Lexiscan (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI). Its products under clinical development comprise Tecadenoson, which is in Phase III clinical trials product for the potential reduction of rapid heart rate during acute atrial arrhythmias, and in Phase II clinical trials for acute atrial fibrillation; Adentri, a Phase III clinical studies product for heart failure; CVT-6883, a Phase I clinical trial product to treat cardiopulmonary diseases; and CVT-3619, a Phase I clinical studies drug for diabetes/metabolic syndrome. The company s products under preclinical trials include Tecadenoson for atrial fibrillation; CVT-10,216 to treat alcohol addicted patients; Late I for the treatment of coronary artery disease; A2A antagonist for chemical dependence; ABCA1/ApoA-I to treat atherosclerosis; and Drug-Eluting Stent Program for the treatment of restenosis. The company has collaborative partnerships with Biogen Idec Inc.; Astellas Pharma, Inc.; Menarini Group; and Roche Palo Alto LLC. Gilead Palo Alto, Inc. was formerly known as CV Therapeutics, Inc. and changed its name to Gilead Palo Alto, Inc. in January 2009. The company was incorporated in 1990 and is based in Foster City, California. As of April 14, 2009, Gilead Palo Alto, Inc. operates as a subsidiary of Gilead Sciences Inc.